A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wtosteosarcoma cells.
Skalniak, L., Twarda-Clapa, A., Neochoritis, C.G., Surmiak, E., Machula, M., Wisniewska, A., Labuzek, B., Ali, A.M., Krzanik, S., Dubin, G., Groves, M., Domling, A., Holak, T.A.(2019) FEBS J 286: 1360-1374
- PubMed: 30715803 
- DOI: 10.1111/febs.14774
- Primary Citation of Related Structures:  
5OAI - PubMed Abstract: 
The p53 protein is engaged in the repair of DNA mutations and elimination of heavily damaged cells, providing anticancer protection. Dysregulation of p53 activity is a crucial step in carcinogenesis. This dysregulation is often caused by the overexpression of negative regulators of p53, among which MDM2 is the most prominent one ...